Marina Garassino, MD, University of Chicago, Chicago, IL, talks on uncommon targets for the treatment of non-small cell lung cancer (NSCLC). Dr Garassino discusses how, whilst many novel targets have been identified, such as ROS1, BRAF, HER2 or MET, these are only present in a small number of patients with NSCLC. Dr Garassino also outlines challenges associated with not all centers being able to perform next-generation sequencing (NGS). This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.